IgA Nephropathy Pipeline Insight

DelveInsight’s, “IgA Nephropathy Pipeline Insight 2026” report provides comprehensive insights about 25+ companies and 30+ pipeline drugs in IgA Nephropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

IgA Nephropathy Understanding

IgA Nephropathy Overview

IgA Nephropathy (IgAN) or Berger’s disease is one of the leading causes of glomerulonephritis and renal failure. This disease is characterized by the deposition of IgA in the glomerular mesangium, which triggers immune-mediated injury to the basement membrane, resulting in hematuria, proteinuria, and impaired kidney function. Pathologically, IgA nephropathy can show a variety of changes in the glomeruli, but the most common feature is an increase in mesangial cells along with noticeable deposits of IgA.

IgA nephropathy (IgAN) results from dysregulated immune activity that causes IgA to accumulate in the glomerulus, increasing podocyte permeability and promoting interstitial fibrosis. While infections may act as triggers, the condition is not directly caused by any specific pathogen; instead, it arises from immune imbalance and genetic influences, particularly those affecting IgA glycosylation. IgAN can be familial in a small proportion of cases (less than 10%), linked to genes such as C1GALT1 and C1GALT1C1, but the majority (over 90%) are sporadic, with no definitive association with infections or dietary antigens, except in rare instances like celiac disease. A key pathogenic feature is the abnormal O-glycosylation of IgA1, which leads to the formation of immune complexes that deposit in the mesangium and contribute to renal injury. 

The diagnosis of IgA nephropathy (IgAN) involves both clinical evaluation and detailed analysis of kidney tissue, most reliably confirmed through a renal biopsy examined by immunofluorescence microscopy. The disease is characterized by the deposition of pathogenic polymeric IgA1 immune complexes in the glomerular mesangium, sometimes accompanied by IgG and IgM, along with mesangial cell proliferation, increased extracellular matrix production, and infiltration of immune cells such as macrophages, monocytes, and T cells. In terms of treatment, the Kidney Disease Improving Global Outcomes (KDIGO) guidelines recommend renin–angiotensin system inhibitors (RASIs) to reduce proteinuria in patients with urinary protein levels above 1 g/day, while corticosteroid therapy is advised for those with persistent proteinuria; studies have shown that combining corticosteroids with RASIs can help lower proteinuria and delay progression to end-stage renal disease (ESRD). 

Treatment of IgA nephropathy (IgAN) focuses on slowing disease progression and preserving kidney function, as no definitive cure exists. It includes supportive measures such as controlling blood pressure and reducing proteinuria, mainly using renin–angiotensin system blockers like ACE inhibitors or ARBs. In patients with persistent or severe disease, corticosteroids or other immunosuppressive therapies may be used to reduce inflammation. Newer targeted therapies, such as budesonide, are also being developed to address the underlying immune mechanisms, with the overall goal of delaying progression to end-stage renal disease. 

"IgA Nephropathy Pipeline Insight 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the IgA Nephropathy pipeline landscape is provided which includes the disease overview and IgA Nephropathy treatment guidelines. The assessment part of the report embraces, in depth IgA Nephropathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, IgA Nephropathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest  IgA Nephropathy pipeline insights, emerging therapies, and clinical advancements shaping the future of treatment in 2026.

IgA Nephropathy Pipeline Report Highlights

• The IgA Nephropathy  companies and academics are working to assess challenges and seek opportunities that could influence IgA Nephropathy R&D. The therapies under development are focused on novel approaches to treat/improve IgA Nephropathy. 

IgA Nephropathy Emerging Drugs Analysis

This IgA Nephropathy segment of the IgA Nephropathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

IgA Nephropathy Emerging Drugs 

Zigakibart (BION-1301): Novartis Pharmaceuticals

Zigakibart is a humanized IgG4 monoclonal antibody that binds the cytokine A Proliferation-Inducing Ligand (APRIL, also known as TNFSF13). APRIL is a critical factor in immunoglobulin (Ig) A nephropathy pathogenesis. By targeting APRIL, zigakibart interferes with B-cell differentiation and the survival of Gd-IgA1–producing plasma cells, thereby leading to decreased Gd-IgA1 levels and consequently reducing immune complex formation, thus exhibiting disease-modifying potential in IgAN. Novartis Pharmaceuticals is currently investigating Zigakibart in Phase III clinical trials for IgA Nephropathy.

BHV-1400: Biohaven, Ltd.

BHV-1400 is a potential first-in-class Gd-IgA1 TRAP degrader, rationally designed to leverage the body's natural hepatic clearance mechanisms to selectively target and remove Gd-IgA1, the underlying cause of the IgA nephropathy and IgA vasculitis. BHV-1400 spares IgG, IgA, IgE, and IgM to preserve patient immune protection against bacteria, viruses and parasites. Currently, according to the company’s pipeline the drug is being evaluated in the Phase I/II stage of its development for the treatment of IgA Nephropathy. 

TST 008: Transcenta Holding

TST 008 is a first-in-class bispecific antibody combining MASP2 antibody with another molecule blocking B-cell activation and/or differentiation. It act as Immunogenetic modulators.  It acts by targeting both the lectin complement pathway and B-cell regulation pathway. TST008 binds to Mannan-binding lectin-associated serine protease-2 (MASP2). By blocking MASP2, TST008 inhibits the lectin pathway of the complement cascade, which is involved in driving inflammatory processes in autoimmune diseases. The molecule is fused with a truncated transmembrane activator and calcium modulator ligand interactor (TACI) protein. This TACI component allows the antibody to bind to ligands such as BAFF (B-cell activating factor) and APRIL (a proliferation-inducing ligand). The drug is being evaluated in preclinical stage of its development for the treatment of IgA Nephropathy. 

Further product details are provided in the report……..

IgA Nephropathy Therapeutic Assessment

This IgA Nephropathy segment of the IgA Nephropathy pipeline report provides insights about the different IgA Nephropathy drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in IgA Nephropathy

There are approx. 25+ key companies which are developing the therapies IgA Nephropathy. The companies which have their IgA Nephropathy drug candidates in the most advanced stage, i.e. Phase III include, Novartis Pharmaceuticals and others.

IgA Nephropathy Trial Phases

DelveInsight’s report covers around 30+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of 
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

IgA Nephropathy Drug Route of Administration

IgA Nephropathy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as 

• Intra-articular
• Intraocular
• Intrathecal 
• Intravenous
• Ophthalmic
• Oral
• Parenteral
• Subcutaneous
• Topical
• Transdermal

IgA Nephropathy Molecule Type

IgA Nephropathy Products have been categorized under various Molecule types such as

• Oligonucleotide
• Peptide
• Small molecule

 IgA Nephropathy Product Type

IgA Nephropathy Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

IgA Nephropathy Clinical Trial Activities

The IgA Nephropathy pipeline report provides insights into IgA Nephropathy Clinical Trials in phase II, I, preclinical and discovery stage. It also analyses IgA Nephropathy therapeutic drugs key players involved in developing key drugs. 

IgA Nephropathy Pipeline Development Activities

The IgA Nephropathy Clinical Trials analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging IgA Nephropathy drugs.

IgA Nephropathy Report Insights

• IgA Nephropathy Pipeline Analysis
• IgA Nephropathy Therapeutic Assessment
• IgA Nephropathy Market Unmet Needs
• Impact of IgA Nephropathy Drugs

IgA Nephropathy Report Assessment

•  IgA Nephropathy Pipeline Product Profiles
•  IgA Nephropathy Therapeutic Assessment
•  IgA Nephropathy Pipeline Assessment
• Inactive IgA Nephropathy drugs assessment
•  IgA Nephropathy Market Unmet Needs

Discover actionable insights into the  IgA Nephropathy market trends, epidemiology trends, and forecast through 2036 to stay ahead in emerging therapies.

Key Questions Answered In The IgA Nephropathy Pipeline Report

Current IgA Nephropathy Treatment Scenario and Emerging Therapies:

• How many IgA Nephropathy companies are developing IgA Nephropathy drugs?
• How many IgA Nephropathy drugs are developed by each company?
• How many IgA Nephropathy emerging drugs are in mid-stage, and late-stage of development for the treatment of IgA Nephropathy?
• What are the key collaborations (Industry–Industry, Industry Academia), Mergers and acquisitions, licensing activities related to the IgA Nephropathy therapeutics? 
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies? 
• What are the clinical studies going on for IgA Nephropathy and their status?
•  What are the IgA Nephropathy key designations that have been granted to the emerging drugs?

IgA Nephropathy Key Players

• Novartis Pharmaceuticals 
• Biohaven, Ltd.
• Keymed Biosciences Co.Ltd
• Guangdong Hengrui Pharmaceutical Co., Ltd.
• ADARx Pharmaceuticals Inc
• Biogen
• Suzhou Rigerna Therapeutics
• Wuxi BioCity Biopharmaceutics Co., Ltd.
• Transcenta Holding
• Climb Bio
• Chengdu Suncadia Medicine Co., Ltd.
• Purespring Therapeutics

IgA Nephropathy Key Products

• Zigakibart 
• BHV-1400
• SC0062
• ADX-038
• CM313
• Felzartamab
• RG-002
• CLYM 116
• SHR 2173
• HRS 5965
• PS-002
• TST 008

Explore comprehensive insights into  IgA Nephropathy epidemiology trends, patient population forecasts, and growth opportunities through 2034 for strategic decision-making.